N/A Completed N=25

Mechanisms of Insulin Resistance in Humans

Inflammation · Insulin Resistance

Source: ClinicalTrials.gov NCT00330967 ↗

Enrolled (actual)

Serious AEs

4.0%

Results posted

Mar 2015

Primary outcomePrimary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio

Summary

The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery. which would cause minimal or no systemic hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during the systemic lipid infusion, and (2) determine the inflammatory response and insulin resistance in skeletal muscle during an infusion of lipid into the femoral artery as described above after NF-KB inhibition by high dose salicylate treatment in humans.

Outcome Measures

Outcome	Result	p-value
PRIMARY Insulin Signaling With Lipid Infusion	0.4334; 0.7276; 0.5264; 0.3534	—
PRIMARY Phos-p38 MAPK Expression With Femoral Lipid and Insulin Infusions	0.000394; 0.001271; 0.000337; 0.000270	—
PRIMARY p38 MAPK Expression With Femoral Lipid and Insulin Infusions	0.000455; 0.001291; 0.000502; 0.000377	—
PRIMARY Phospho-ERK MAPK Expression With Femoral Lipid and Insulin Infusions	0.000091; 0.000108; 0.000096; 0.000092	—
PRIMARY ERK MAPK Expression With Femoral Lipid and Insulin Infusions	0.000103; 0.000158; 0.000124; 0.000114	—
PRIMARY Phospho-JNK MAPK Expression With Femoral Lipid and Insulin Infusions	0.00401; 0.005888; 0.003756; 0.00224	—
PRIMARY JNK MAPK Expression With Femoral Lipid and Insulin Infusions	0.001364; 0.002996; 0.002151; 0.001783	—

Eligibility Criteria

Inclusion Criteria

two groups of 16 healthy subjects

Exclusion Criteria

diabetes or impaired glucose tolerance
peripheral vascular disease
pulmonary disease
clinically significant hepatic or renal disease
triglycerides >200mg/dl
anemia
abnormal PT, PTT or INR
pregnancy or lactation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00330967). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.